Fluidigm, Novartis Amend MDx Alliance

In the amended deal, a milestone payment for which Fluidigm may be eligible has been increased, and the time period during which Novartis may license the technology being developed was also modified.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.